News

Multimedia

Conferences

Publications

Brand Insights

Resources

Sustainability
DE&I
Pandemic
Finance
Legal
Technology
Regulatory
Global
Pricing
Strategy
R&D/Clinical Trials
Opinion
Executive Roundtable
Sales & Marketing
Executive Profiles
Leadership
Market Access
Patient Engagement
Supply Chain
Industry Trends

Pfizer Taps Harvard's Ole Isacson as CSO of Neuroscience Research Unit

September 12, 2016

Article

September 12, 2016

Pfizer has announced that Dr. Ole Isacson will become its Chief Scientific Officer of the Neuroscience Research Unit and Senior Vice President, effective September 16.

Dr. Isacson is a Professor of Neurology at Harvard Medical School, and will continue to serve in an educational role. He is also a founding director of the Neuroregeneration Institute at McLean Hospital.

Dr. Isacson will report directly to Mikael Dolsten, President of Worldwide Research and Development.

Related Content

AI in Pharma: Where, When, and How Executives are Considering it

Gaugarin Oliver

November 19th 2024

Article

As skepticism surrounding AI fades, pharma industry execs are ready to embrace the technology.

Drilling in on Disease Hallmarks: New Tricks to Solve Age-Old Problems

Mike Hollan

November 15th 2024

Article

Ann Beliën, PhD, founder and CEO of Rejuvenate Biomed, discusses how AI is being used to find new ways to treat age-related conditions.

The Leap Forward: Practical Gains for Pharma AI Use

Bianca Anghelina;Helen Merianos;Ruth Beadle

November 14th 2024

Article

Exploring those areas and functions where the application of generative artificial intelligence—through use cases borne out in practice—are demonstrating tangible value and driving life sciences innovation to new heights.